ACADIA Pharmaceuticals (FRA:DR6) COGS-to-Revenue : 0.11 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals COGS-to-Revenue?

ACADIA Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was €21.1 Mil. Its Revenue for the three months ended in Mar. 2024 was €189.4 Mil.

ACADIA Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2024 was 0.11.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ACADIA Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 was 88.85%.

ACADIA Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for ACADIA Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals COGS-to-Revenue Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.06

0.05

0.04

0.02

0.06

ACADIA Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.01	0.05	0.07	0.08	0.11

ACADIA Pharmaceuticals COGS-to-Revenue Calculation

ACADIA Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	38.182	/	666.143
	=	0.06

ACADIA Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21.115	/	189.365
	=	0.11

ACADIA Pharmaceuticals (FRA:DR6) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ACADIA Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	21.115 / 189.365
	=	88.85 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ACADIA Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (FRA:DR6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ACAD:USA

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines